CTOs on the Move

Nautilus

www.nautilus.com

 
Nautilus, Inc. is an iconic industry leader with a rich history and reputation as an innovative company building the best cardio and strength equipment for home use. Known for its family of brands that includes Bowflex®, Nautilus®, and Schwinn® Fitness, Nautilus, Inc. develops, manufacturers and markets branded products that include strength, cardio and fitness accessories through direct and retail channels. With its headquarters and innovation center located in Vancouver, Washington, Nautilus, Inc. employs nearly 500 employees and has offices in Brooklyn Park, Minnesota and Shanghai, China, as well as distribution centers in Portland, Oregon, Columbus, Ohio, and Rotterdam, The Netherlands.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Garry Wiseman
 Senior Vice President and Chief Digital Officer Profile

Similar Companies

Teva Neuroscience

Teva Neuroscience is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Kansas City, MO. To find more information about Teva Neuroscience, please visit www.tevaneuro.com

Parfums De Coeur Ltd

Parfums De Coeur Ltd is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Darien, CT. To find more information about Parfums De Coeur Ltd, please visit www.pdcltd.com

Innovative Living Inc

Innovative Living Inc is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hydrogen Health

Hydrogen Health is a virtual primary care solution that brings K Healths suite of digital healthcare services to employers and health plans, increasing positive long term health outcomes while substantially reducing costs.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.